BOSTON--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced positive study results at the American Academy of Dermatology’s (AAD) Summer Academy Meeting in Boston, Mass., showing that the use of its Condition & Enhance System, when combined with Botulinum Toxin Type A treatments (BOTOX®), provides greater improvement in overall facial appearance, as well as increased patient satisfaction, vs. BOTOX treatments with placebo.
